Recurrent glioblastoma: Does the timing of bevacizumab treatment impact survival?

Susmita Sakruti; Jaskirat Singh Randhawa; Sandra D. Griffith; Glen Stevens; David M. Peereboom; Manmeet Singh Ahluwalia

doi:10.1200/JCO.2014.32.15_SUPPL.2039

Recurrent glioblastoma: Does the timing of bevacizumab treatment impact survival?

Susmita Sakruti
, Jaskirat Singh Randhawa
, Sandra D. Griffith
, Glen Stevens
, David M. Peereboom
, Manmeet Singh Ahluwalia

Herbert Wertheim Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	32
DOIs	https://doi.org/10.1200/JCO.2014.32.15_SUPPL.2039
State	Published - May 20 2014

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1200/JCO.2014.32.15_SUPPL.2039License: Unspecified

Cite this

@article{701d42e563cd42148622b5fbac848d97,

title = "Recurrent glioblastoma: Does the timing of bevacizumab treatment impact survival?",

author = "Susmita Sakruti and Randhawa, \{Jaskirat Singh\} and Griffith, \{Sandra D.\} and Glen Stevens and Peereboom, \{David M.\} and Ahluwalia, \{Manmeet Singh\}",

note = "2039 Background: Bevacizumab (Bev) is FDA approved for use in recurrent glioblastoma (rGBM). There is limited literature on outcomes in rGBM depending on the time of initiation of Bev therapy. We examined the progression-free survival (PFS) and overall survival (OS) in rGBM patients treated with Bev at our center.",

year = "2014",

month = may,

day = "20",

doi = "10.1200/JCO.2014.32.15\_SUPPL.2039",

language = "American English",